What Is Dihexa?

1. What kind of compound is Dihexa?

Dihexa comes from research into angiotensin IV, a six-amino-acid peptide investigated for effects on learning and memory. Researchers modified a smaller part of that structure to make a compound less vulnerable to breakdown and better able to cross biological barriers. A peptidomimetic is a molecule designed around features of a peptide, with chemical changes that can alter how it behaves.

The 2013 McCoy paper introduced Dihexa as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. That chemical name and the code PNB-0408 help distinguish the studied molecule from similarly marketed products. The paper now carries a notice of concern, so its pharmacology needs to be read with that qualification.

2. How is Dihexa supposed to work?

The proposed mechanism involves hepatocyte growth factor, or HGF, and its receptor, c-Met. HGF is a signaling protein. When it binds c-Met, it can activate pathways involved in cell survival, growth and movement. Despite the reference to liver cells in its name, this signaling system has functions beyond the liver. NIH’s MET record describes those broader roles.

Dihexa researchers proposed that it increases HGF’s activity at c-Met, helping neurons develop synaptic connections. A synapse is a junction through which neurons communicate. Dendritic spines are small projections on neurons that receive many of those connections; researchers can count them under a microscope.

More spines in cultured neurons would be a reason to investigate learning. It would not establish better recall in people, growth of new neurons or repair of an injured human brain. Synapse formation and neurogenesis, the production of new neurons, are different processes.

The specific claim that Dihexa’s effects depend on HGF/c-Met came from a 2014 paper that is now retracted. HGF/c-Met remains a real biological pathway. Dihexa’s proposed action on it needs credible independent confirmation.

3. What happened to the Dihexa research papers?

Two publication records affect many of the claims repeated about Dihexa:

The 2025 notice reports that a Washington State University investigation found falsified or fabricated data in specified figures and a subsequent erratum submission. This was a research-integrity finding, rather than a routine correction of a typo.

The retraction does not prove that Dihexa has no biological activity. It weakens the evidence for the mechanism used to explain that activity. Later studies must be assessed on their own methods, especially when their explanation relies on the withdrawn paper.

4. Dihexa benefits: what did the animal studies find?

The main cognition experiments include early positive findings, a later positive mouse study and a negative rat study. Their models differ, so they cannot be combined into a single success rate.

In the Sun experiment, the Morris water maze tested whether mice learned the location of a hidden platform. Dihexa-treated mice found it faster during parts of training and crossed its former location more often after removal. Swimming speed did not differ between groups, which helps address one alternative explanation for the result.

The researchers also reported higher synaptophysin, a protein used as a synaptic marker, and changes in inflammation-related measurements. Blocking PI3K signaling reversed some reported effects. These findings support further experiments on the pathway; they do not measure how much faster a healthy adult could learn a language.

The treatment section describes both intragastric administration, into the stomach, and intraperitoneal administration, into the abdominal cavity. That inconsistency prevents using this study as clear evidence for a particular delivery route.

Wells and colleagues tested a different question: whether Dihexa protected rats exposed to a mitochondrial toxin that produces Huntington’s-like symptoms. It did not. A positive Alzheimer’s-model result cannot justify describing Dihexa as broadly protective against neurological disease.

5. Is Dihexa “10 million times stronger than BDNF”?

That phrase cannot tell you how much better anyone will remember, focus or learn. BDNF, or brain-derived neurotrophic factor, is a protein involved in neuronal survival and plasticity. It is not a standardized unit of cognitive improvement.

A laboratory potency comparison asks how much of a substance produces a particular response under particular conditions. It requires the same assay, a defined endpoint and comparable concentration-response measurements. Even a valid concentration ratio would leave absorption, brain exposure, maximum effect and toxicity unanswered.

The early Dihexa work examined synaptic measurements in cultured rat neurons. It did not compare human memory improvement against BDNF. Its publication-integrity warning is an additional reason to avoid turning laboratory concentration claims into a performance multiplier. There is no demonstrated “10 million-fold” cognitive benefit in people.

6. Has Dihexa been tested in humans?

A ClinicalTrials.gov search for Dihexa or PNB-0408 returned no registered studies when checked on September 20, 2026. The literature search for this guide did not identify a published human trial establishing cognitive benefit. A registry search cannot exclude every unregistered exposure or study under another name.

The FDA’s dihexa acetate entry separately states that it has identified no human exposure data for drug products containing that substance through any route. Forum reports do not supply the verified products, comparison groups or systematic safety follow-up of a clinical study.

What about fosgonimeton and the Alzheimer’s trials?

Fosgonimeton, also called ATH-1017, belongs to a clinical development program targeting HGF/MET. Its development paper identifies the active metabolite as fosgo-AM, previously ATH-1001. A shared pathway does not establish equivalence to a product sold as Dihexa.

In September 2024, Athira reported that its Phase 2/3 LIFT-AD trial did not meet its primary endpoint or key secondary endpoints for cognition and daily function. The trial cannot be cited as proof that Dihexa improves human memory. Its failure also does not directly test every Dihexa claim; the studied treatment and population must remain attached to the result.

7. Dihexa dosage, half-life and delivery routes

There is no validated human cognitive-enhancement dose, cycle or maintenance schedule. Converting an animal dose by body weight cannot supply missing human safety and exposure data. Likewise, an online protocol’s precision does not establish that its intervals were tested.

The much-repeated long half-life comes from the 2013 rat paper, which carries the notice of concern:

These are small animal estimates with substantial uncertainty. They also measure clearance, not the duration of a cognitive effect. A half-life curve generated from those values would model an assumption about human exposure.

Oral activity and blood-brain barrier penetration were reported in the early animal work. Human bioavailability still needs to be measured for the exact formulation and route. No reliable human comparison establishes an advantage for oral, topical, intranasal or injectable Dihexa. Changing the route cannot fix the absence of a tested human regimen.

8. Dihexa side effects and the cancer question

Human safety data are too limited to assign dependable frequencies to headaches, anxiety, insomnia or other symptoms described online. Nor can the literature establish that Dihexa avoids tolerance, withdrawal or interactions with psychiatric medicines. There is no adequate clinical basis for describing long-term use as safe.

Cancer concerns arise from the proposed mechanism. NIH describes MET as a proto-oncogene: a gene with normal biological functions that can contribute to cancer when altered or abnormally active. MET mutations, amplification and overexpression are associated with several human cancers.

That gives researchers a reason to investigate whether a compound proposed to enhance this pathway could affect tumor growth. It does not establish that Dihexa causes cancer, and there are no human data here from which to calculate an added risk. Uncertainty about Dihexa’s mechanism also prevents predicting that risk confidently from the pathway alone.

Product quality is a separate question. An identity or purity report does not establish human safety, correct exposure or the suitability of a finished preparation for a particular route. Even accurately labeled material would leave the clinical questions unresolved.

FDA currently places dihexa acetate under substances nominated for compounding but withdrawn. That administrative status does not grant drug approval or answer the agency’s stated safety concerns.

9. Dihexa vs Semax and Selank

These compounds appear together in biohacking discussions, but their evidence comes from different experiments. Semax has small human attention and brain-imaging studies. Selank has small human anxiety studies. Those findings remain preliminary and do not make either a proven option for routine cognitive enhancement.

Dihexa lacks comparable direct human evidence in the research reviewed here. There is also no controlled human basis for claiming that combining it with Semax or Selank improves results, offsets side effects or produces lasting brain repair. A theory about complementary pathways cannot establish a safe stack ratio.

For a claim about faster learning, look for a controlled human study that measures learning and delayed recall, accounts for practice effects, and follows adverse events over time. For “permanent benefits,” look for testing after treatment has stopped. A study counting neuronal projections or measuring a signaling protein cannot answer either question.

10. Dihexa FAQ

• What is Dihexa used for?

  Dihexa is an experimental molecule studied for memory and neuronal connections in laboratory and animal models. It is marketed as a nootropic, but human research has not established benefits for focus, learning or brain fog.

• Is Dihexa a peptide?

  Dihexa is usually described as an angiotensin IV-derived peptidomimetic: a chemically modified molecule built from part of a peptide's structure. It is also called PNB-0408.

• Does Dihexa grow new brain cells?

  Early research reported increased dendritic spines and synaptic activity in cultured rat neurons. These findings do not demonstrate new neurons or brain regeneration in humans, and the original study carries a notice of concern.

• Is Dihexa 10 million times stronger than BDNF?

  That claim does not describe a measured human memory benefit. Comparing concentrations in a cell experiment cannot establish superior cognition, a human dose or safety. Dihexa's core mechanism literature also has publication-integrity problems.

• Does Dihexa cause cancer?

  Human studies have not established whether Dihexa increases cancer risk. Concern comes from its proposed HGF/c-Met mechanism, because abnormal MET signaling can support cancer. That biological concern cannot quantify an individual's risk or establish that Dihexa causes cancer.

• What is the recommended Dihexa dosage?

  There is no validated human dose or cycle for cognitive enhancement. Animal doses and online anecdotes cannot establish a safe starting dose, maintenance schedule or stack.

• What is Dihexa's half-life?

  A dependable human half-life is unknown. The often-cited multi-day figures came from small rat experiments in a paper that now carries a notice of concern; they cannot determine a human redosing interval.

• Is oral Dihexa better than topical or injectable Dihexa?

  No reliable human comparison establishes a preferred route. Animal findings do not validate the absorption, brain exposure or safety of capsules, creams, nasal products or injections sold for human use.

• Is Dihexa FDA-approved?

  Dihexa has no FDA-approved medical use as of September 20, 2026. FDA lists dihexa acetate among substances nominated for compounding but withdrawn, and says it lacks human exposure data and important safety information.

• Can Dihexa be stacked with Semax or Selank?

  Controlled human evidence has not established the safety or added benefit of these combinations. Different proposed mechanisms do not demonstrate synergy or supply a safe stack ratio.

11. Sources